135 related articles for article (PubMed ID: 16278391)
1. Role of activating fibroblast growth factor receptor 3 mutations in the development of bladder tumors.
Zieger K; Dyrskjøt L; Wiuf C; Jensen JL; Andersen CL; Jensen KM; Ørntoft TF
Clin Cancer Res; 2005 Nov; 11(21):7709-19. PubMed ID: 16278391
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic and Prognostic Implications of FGFR3
Geelvink M; Babmorad A; Maurer A; Stöhr R; Grimm T; Bach C; Knuechel R; Rose M; Gaisa NT
Int J Mol Sci; 2018 Aug; 19(9):. PubMed ID: 30154342
[TBL] [Abstract][Full Text] [Related]
3. FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy.
Kompier LC; Lurkin I; van der Aa MN; van Rhijn BW; van der Kwast TH; Zwarthoff EC
PLoS One; 2010 Nov; 5(11):e13821. PubMed ID: 21072204
[TBL] [Abstract][Full Text] [Related]
4. Proteogenomic Characterization of Bladder Cancer Reveals Sensitivity to Apoptosis Induced by Tumor Necrosis Factor-related Apoptosis-inducing Ligand in FGFR3-mutated Tumors.
Groeneveld CS; Sanchez-Quiles V; Dufour F; Shi M; Dingli F; Nicolle R; Chapeaublanc E; Poullet P; Jeffery D; Krucker C; Maillé P; Vacherot F; Vordos D; Benhamou S; Lebret T; Micheau O; Zinovyev A; Loew D; Allory Y; de Reyniès A; Bernard-Pierrot I; Radvanyi F
Eur Urol; 2024 May; 85(5):483-494. PubMed ID: 37380559
[TBL] [Abstract][Full Text] [Related]
5. Clinical and Genomic Landscape of FGFR3-Altered Urothelial Carcinoma and Treatment Outcomes with Erdafitinib: A Real-World Experience.
Guercio BJ; Sarfaty M; Teo MY; Ratna N; Duzgol C; Funt SA; Lee CH; Aggen DH; Regazzi AM; Chen Z; Lattanzi M; Al-Ahmadie HA; Brannon AR; Shah R; Chu C; Lenis AT; Pietzak E; Bochner BH; Berger MF; Solit DB; Rosenberg JE; Bajorin DF; Iyer G
Clin Cancer Res; 2023 Nov; 29(22):4586-4595. PubMed ID: 37682528
[TBL] [Abstract][Full Text] [Related]
6. Dysregulated FGFR3 signaling alters the immune landscape in bladder cancer and presents therapeutic possibilities in an agent-based model.
Bergman DR; Wang Y; Trujillo E; Fernald AA; Li L; Pearson AT; Sweis RF; Jackson TL
Front Immunol; 2024; 15():1358019. PubMed ID: 38515743
[TBL] [Abstract][Full Text] [Related]
7. Analysis of Several Common APOBEC-type Mutations in Bladder Tumors Suggests Links to Viral Infection.
Rao N; Starrett GJ; Piaskowski ML; Butler KE; Golubeva Y; Yan W; Lawrence SM; Dean M; Garcia-Closas M; Baris D; Johnson A; Schwenn M; Malats N; Real FX; Kogevinas M; Rothman N; Silverman DT; Dyrskjøt L; Buck CB; Koutros S; Prokunina-Olsson L
Cancer Prev Res (Phila); 2023 Oct; 16(10):561-570. PubMed ID: 37477495
[TBL] [Abstract][Full Text] [Related]
8. P53, CK20, and FGFR3 Overexpression is Associated with the Characteristics of Urothelial Cell Carcinoma of the Bladder.
Asgari M; Firouzi F; Abolhasani M; Bahadoram M; Barahman M; Madjd Z; Mehrazam M; Hassanzadeh S; Akade E
Asian Pac J Cancer Prev; 2023 Sep; 24(9):3125-3131. PubMed ID: 37774064
[TBL] [Abstract][Full Text] [Related]
9. Using deep learning to identify bladder cancers with FGFR-activating mutations from histology images.
Velmahos CS; Badgeley M; Lo YC
Cancer Med; 2021 Jul; 10(14):4805-4813. PubMed ID: 34114376
[TBL] [Abstract][Full Text] [Related]
10. An FGFR3/MYC positive feedback loop provides new opportunities for targeted therapies in bladder cancers.
Mahe M; Dufour F; Neyret-Kahn H; Moreno-Vega A; Beraud C; Shi M; Hamaidi I; Sanchez-Quiles V; Krucker C; Dorland-Galliot M; Chapeaublanc E; Nicolle R; Lang H; Pouponnot C; Massfelder T; Radvanyi F; Bernard-Pierrot I
EMBO Mol Med; 2018 Apr; 10(4):. PubMed ID: 29463565
[TBL] [Abstract][Full Text] [Related]
11. Oncogenic PIK3CA mutations occur in epidermal nevi and seborrheic keratoses with a characteristic mutation pattern.
Hafner C; López-Knowles E; Luis NM; Toll A; Baselga E; Fernández-Casado A; Hernández S; Ribé A; Mentzel T; Stoehr R; Hofstaedter F; Landthaler M; Vogt T; Pujol RM; Hartmann A; Real FX
Proc Natl Acad Sci U S A; 2007 Aug; 104(33):13450-4. PubMed ID: 17673550
[TBL] [Abstract][Full Text] [Related]
12. FGFR3 Alterations in Bladder Cancer Stimulate Serine Synthesis to Induce Immune-Inert Macrophages That Suppress T-cell Recruitment and Activation.
Ouyang Y; Ou Z; Zhong W; Yang J; Fu S; Ouyang N; Chen J; Xu L; Wu D; Qian J; Lin Y; Lin T; Huang J
Cancer Res; 2023 Dec; 83(24):4030-4046. PubMed ID: 37768887
[TBL] [Abstract][Full Text] [Related]
13.
Yu SH; Kim SS; Kim S; Lee H; Kang TW
J Clin Med; 2024 Feb; 13(5):. PubMed ID: 38592174
[No Abstract] [Full Text] [Related]
14. [Clinical characteristics and prognosis of newly diagnosed multiple myeloma patients with FGFR3 gene mutations].
Shen N; Zhang J; Xia Y; Shen XX; Wang J; Jin YY; Zhang R; Li JY; Chen LJ
Zhonghua Xue Ye Xue Za Zhi; 2023 Dec; 44(12):989-994. PubMed ID: 38503521
[No Abstract] [Full Text] [Related]
15. Pure Large Nested Variant of Urothelial Carcinoma (LNUC) Is the Prototype of an
Weyerer V; Eckstein M; Compérat E; Juette H; Gaisa NT; Allory Y; Stöhr R; Wullich B; Rouprêt M; Hartmann A; Bertz S
Cancers (Basel); 2020 Mar; 12(3):. PubMed ID: 32213857
[TBL] [Abstract][Full Text] [Related]
16. Canine fibroblast growth factor receptor 3 sequence is conserved across dogs of divergent skeletal size.
Smith LB; Bannasch DL; Young AE; Grossman DI; Belanger JM; Oberbauer AM
BMC Genet; 2008 Oct; 9():67. PubMed ID: 18940000
[TBL] [Abstract][Full Text] [Related]
17. Central neurocytoma exhibits radial glial cell signatures with FGFR3 hypomethylation and overexpression.
Lee Y; Chowdhury T; Kim S; Yu HJ; Kim KM; Kang H; Kim MS; Kim JW; Kim YH; Ji SY; Hwang K; Han JH; Hwang J; Yoo SK; Lee KS; Choe G; Won JK; Park SH; Lee YK; Shin JH; Park CK; Kim CY; Kim JI
Exp Mol Med; 2024 Apr; 56(4):975-986. PubMed ID: 38609519
[TBL] [Abstract][Full Text] [Related]
18. Multiomics profiling of urothelial carcinoma
Anurag M; Strandgaard T; Kim SH; Dou Y; Comperat E; Al-Ahmadie H; Inman BA; Taber A; Nordentoft I; Jensen JB; Dyrskjøt L; Lerner SP
iScience; 2024 Mar; 27(3):109179. PubMed ID: 38439961
[TBL] [Abstract][Full Text] [Related]
19. Publisher Correction: Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trial.
Rodón J; Damian S; Furqan M; García-Donas J; Imai H; Italiano A; Spanggaard I; Ueno M; Yokota T; Veronese ML; Oliveira N; Li X; Gilmartin A; Schaffer M; Goyal L
Nat Med; 2024 May; ():. PubMed ID: 38789647
[No Abstract] [Full Text] [Related]
20. Emergence of FGFR family gene fusions as therapeutic targets in a wide spectrum of solid tumours.
Parker BC; Engels M; Annala M; Zhang W
J Pathol; 2014 Jan; 232(1):4-15. PubMed ID: 24588013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
